Research

Engaging Research to Achieve Cancer Care Equity

Webinar: Clinical Trials – Optimizing Diversity, Equity & Inclusivity

Join panelists from the National Cancer Institute, Vanderbilt-Ingram Cancer Center, AstraZeneca, and ConcertAI to build an understanding of: obstacles that restrict patient diversity in clinical trials; how clinical researchers can strike the correct balance of scientific and ethical imperatives to ensure equitable access and outcomes in clinical research; and how sponsors, patients and investigators have overcome historical biases in clinical trials.

Webinar: ERACE: Building Research and Knowledge to Eliminate Disparities

In a focused discussion among pharmaceutical executives and academic researchers, we explore 1) the historical and anticipated contributors to inequities in cancer care; 2) the organizational overhaul needed to effect change; 3)  and how local, state and federal regulations and incentives can move the industry forward such that we may achieve health equity for all patients.

ERACE Research Award

Announcing Award Recipients

We are pleased to announce that two grant applications have been accepted for the ERACE Research Award. The grant includes access to ERACE’s Real-world data (RWD) patient registry in support of cancer disparity research.

 

 

 

RESEARCH

2021 ASCO Annual Meeting

Read the latest research focused on racial differences in demographics, diagnoses and symptoms among oncology patients.

Assessment of differences in demographic characteristics and clinical diagnoses among black and white oncology patients with COVID

Read More

Differences by race in patient-reported symptoms during chemotherapy among women with early-stage, hormone receptor-positive breast cancer

Read More

See more ConcertAI  research published at the 2021 ASCO Annual Meeting.

Read More

Partnerships

The partnerships and collaborations formed under ERACE
reaffirm our commitment toward achieving cancer health equity

 

National Cancer Institute          ASCO          Janssen          Bristol Myers Squibb
Yale University School of Medicine          AmeriHealth          Syneos Health
The Roux Institute at Northeastern University
News

Notable Press and Media

Racial disparities in Covid-19 are bad. They’re even worse in cancer.

The currents of the racial justice movement and the Covid-19 pandemic have amplified persistent and pernicious disparities in access and outcomes across so many aspects of American life, including cancer care.

Many people are aware of the dire — and disproportionate — consequences that Covid-19 has had on the Latinx and Black American communities. New research shows that newly diagnosed Black cancer patients are at a higher risk of severe Covid-19 than white patients.

Read More

Why Cancer Registries are Part of America’s Fight for Racial Equality

According to a 2019 study in the Proceedings of the National Academy of Sciences, one in 1,000 Black males can expect to die at the hands of the police. Black males were also 2.5 times more likely to die during an encounter with police than white males. For some, those figures are staggering. For many others, they are reminders of the racial disparities that have existed for far too long in this country.

So, in 2020, when recent events have brought racial injustice back into the national spotlight, it is important to take a closer look at all aspects of life where inequities exist – and not just in the criminal justice system.

Read More
On-Demand Webinar

When It All Works: Case Studies for Success With Patient Diversity in Clinical Trials

How are clinical trials with increased patient diversity leading to more successful treatments? While industry progress towards diverse clinical trials has been slow, there are many inspiring cases where more inclusive patient populations have been used to provide effective treatments for the communities that need them. How can early development of sound clinical and ethical expectations for a trial drive better outcomes? What difference does it make to apply business intelligence and analytics to the challenges of diversity? Join this discussion with industry experts to learn how a trial sponsor or CRO makes this work.

Watch Now

ACRPtv – Spotlight On… Confronting Disparities in Cancer Research

“It’s unfortunate that racial inequality in healthcare [and cancer research] has been around for decades, and it’s something that only recently has come back into the forefront because of the pandemic,” Whyte says in our December 8, 2020 conversation. “I’ve been pleased to see a number of institutions this year start to do something about it,” he adds. Whyte also discusses his own initiatives in the field trying to address cancer care inequities through education and outreach.

Watch Now

Health Disparities in Cancer Care

Minorities in the US bear a disproportionate burden of cancer compared with other population groups. The health disparities and measurable differences in outcomes manifest across the cancer care continuum, from prevention and diagnosis, through treatment, monitoring and mortality.

This understanding guided ConcertAI to form ERACE (Engaging Research to Achieve Cancer Care Equity), a multidisciplinary initiative to better understand cancer disparities and create innovative solutions to eliminate them.

erace

ERACE Advisory Board

ERACE has partnered with institutions and investigators in cancer inequities

Otis W. Brawley, MD

Otis Webb Brawley is an American physician and the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He served as Chief Medical and Scientific Officer and Executive Vice President of the American Cancer Society from 2007 to 2018.

Tuya Pal, MD

Tuya Pal is Associate Director of Cancer Health Disparities and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center, a practicing Clinical Geneticist focused on Inherited Cancers, and Professor of Medicine at the Vanderbilt University Medical Center.

Christopher Lathan, MD, MS, MPH

Chris Lathan is a Medical Director at the Dana-Farber Cancer Institute, a Faculty Director at the Cancer Care Equity Program, Pulmonary Oncologist and Assistant Professor of Medicine at Harvard Medical School.

Erica Warner, ScD, MPH

Dr. Warner is an Assistant Professor in the Department of Medicine at Harvard Medical School and an Assistant Investigator at MGH. She is a member of the Dana-Farber Harvard Cancer Center in the Cancer Epidemiology and Risk and Health Disparities Programs.

asco quality care symposium

Racial Disparities in Performance Status

A new study by ConcertAI based on patient-reported outcomes makes another compelling case for addressing disparities in treatment outcomes and racially biased access to clinical trials – and for why a new research focus is imperative.

See Full Study
Methods

Retrospective Study of Self-Assessed Performance Status (ECOG)

Background
  • Clinical trials lack adequate number of racial minorities.
  • Performance status often a criterion for clinical research.
  • Poor performance status can exclude patients from clinical trial participation.
Patient in Study
0

  • 55.4% White
  • 38.0% Black
Results

Black patients overall reported higher average ECOG scores and greater difficulty performing daily functions than White patients.

Patients reporting not being able to take care of themselves

0%

Blacks

0%

Whites

Conclusion

Significant racial disparities exist in performance status at an initial visit to an oncology clinic and, for Black patients, could mean:
• Lower quality medical care pre-diagnosis
• Poorer outcomes
• Exclusion from clinical trials

Patient Registry

The ERACE Patient Registry is foundational to its mission of eliminating inequities.

The registry provides a real-world view of potential differences in clinical practice, patient outcomes, safety, and comparative effectiveness among cancer patients of color and other marginalized groups.

erace erace erace erace erace erace

Measurable Differences Among Minorities

 
2x

Black American women are 2x as likely to be diagnosed with triple negative breast cancer (TNBC) compared to white women.

0%

Black American men are 37% more likely to develop lung cancer than white men.

0%

Hispanic men are 10% less likely to be diagnosed with prostate cancer than non-Hispanic white men.

0%

American Indian/Alaska Native men are 40% more likely to have stomach cancer than white men, and 2x as likely to die from it.

0%

Liver cancer death rate is 60% higher in Asian Americans compared to whites.

Learn more about ERACE